Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!! -- Ignore unavailable to you. Want to Upgrade?

To: Spiney who wrote (51)	1/12/1999 10:38:00 AM
From: Stephen O	Respond to of 86

I'll check with them later but I am sure that both trials will run simultaneously, they have enough of the drug on hand. You're right the US with the FDA is the big one. They are using a new PR group Tandem Capital group. In their news release, from Tandem, they quote a study done by Ernst & Young that biotech companies on average with a phase 1 trial had a market cap of $100 million, for phase 1 cancer drugs the average number is $52 million. Compare that to IGT's mkt cap of about $8 million. We have a long way to go.